Search Results - "ARNAIZ, Joan A"

Metabolic, mitochondrial, renal and hepatic safety of enfuvirtide and raltegravir antiretroviral administration: Randomized crossover clinical trial in healthy volunteers by Barroso, Sergio, Morén, Constanza, González-Segura, Àlex, Riba, Neus, Arnaiz, Joan A, Manriquez, Marcela, Santana, Gemina, Blanco, José L, Larousse, María, Loncà, Montse, Lazzari, Elisa de, Llopis, Jaume, Mallolas, Josep, Miró, Oscar, Carné, Xavier, Gatell, Jose M, Garrabou, Glòria, Martínez, Esteban

“…Classical antiretroviral agents may acutely impact on metabolic, mitochondrial, renal and hepatic function in HIV-infected and uninfected persons. Fusion and…”
Get full text

Pharmacogenetic study focused on fluoxetine pharmacodynamics in children and adolescent patients: impact of the serotonin pathway by Mas, Sergi, Blázquez, Ana, Rodríguez, Natalia, Boloc, Daniel, Lafuente, Amalia, Arnaiz, Joan A, Lázaro, Luisa, Gassó, Patricia

“…OBJECTIVEPharmacogenetic studies of fluoxetine in children and adolescents are scarce. After reporting the effect of genetic variants in genes related to the…”
Get full text

A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection by Leal, Lorna, León, Agathe, Torres, Berta, Inciarte, Alexy, Lucero, Constanza, Mallolas, Josep, Laguno, Montserrat, Martínez-Rebollar, María, González-Cordón, Ana, Manzardo, Christian, Rojas, Jhon, Pich, Judit, Arnaiz, Joan A, Gatell, Josep M, García, Felipe

“…The objective of this study was to assess post-exposure prophylaxis (PEP) non-completion at day 28, comparing two regimens. A prospective, open, randomized…”
Get full text

A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection by Leal, Lorna, León, Agathe, Torres, Berta, Inciarte, Alexy, Lucero, Constanza, Mallolas, Josep, Laguno, Montserrat, Martínez-Rebollar, María, González-Cordón, Ana, Manzardo, Christian, Rojas, Jhon, Pich, Judit, Arnaiz, Joan A, Gatell, Josep M, García, Felipe

“…The objective of this study was to assess post-exposure prophylaxis (PEP) non-completion at day 28, comparing ritonavir-boosted lopinavir versus maraviroc,…”
Get full text

A Simplification Trial Switching From Nucleoside Reverse Transcriptase Inhibitors to Once-Daily Fixed-Dose Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV-1-Infected Patients With Virological Suppression by Martínez, Esteban, Arranz, José A, Podzamczer, Daniel, Loncá, Montserrat, Sanz, José, Barragán, Patricia, Ribera, Esteban, Knobel, Hernando, Roca, Victor, Gutiérrez, Félix, Blanco, José L, Mallolas, Josep, Llibre, Josep M, Clotet, Bonaventura, Dalmau, David, Segura, Ferran, Arribas, José R, Cosín, Jaime, Barrufet, Pilar, Casas, Esperanza, Ferrer, Elena, Curran, Adrià, González, Alicia, Pich, Judit, Cruceta, Ana, Arnaiz, Joan A, Miró, José M, Gatell, José M

“…BACKGROUND:Data comparing abacavir/lamivudine versus tenofovir/emtricitabine in antiretroviral-naive patients are controversial. We compared 48-week efficacy…”
Get full text

The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients by MILINKOVIC, Ana, MARTINEZ, Esteban, LEON, Agathe, LARROUSSE, Maria, LONCA, Montserrat, MALLOLAS, Josep, GATELL, José M, LOPEZ, Sonia, DE LAZZARI, Elisa, MIRO, Oscar, VIDAL, Sergi, BLANCO, José L, GARRABOU, Gloria, LAGUNO, Montserrat, ARNAIZ, Joan A

“…Stavudine (d4T)-containing regimens are associated with a potential for lipoatrophy and dyslipidaemia. We assessed the safety and efficacy of reducing the dose…”
Get full text

Health-related quality of life in HIV patients switching to twice-daily indinavir/ritonavir regimen or continuing with three-times-daily indinavir-based therapy by BADIA, Xavier, PODZAMCZER, Daniel, MORAL, Irene, ROSET, Montse, ARNAIZ, Joan A, LONCA, Montse, CASIRO, Arnaldo, ROSON, Beatriz, GATELL, Jose M

“…To evaluate health-related quality of life (HRQoL) changes in patients treated with indinavir three-times daily after switching to a twice-daily…”
Get full text

Dose-Finding Study of Once-Daily Indinavir/Ritonavir Plus Zidovudine and Lamivudine in HIV-Infected Patients by Mallolas, Josep, Blanco, José L, Sarasa, María, Giner, Vicenç, Martínez, Esteban, García-Viejo, Miguel A, Arnaiz, Joan A, Cruceta, Anna, Soy, Dolors, Tuset, Montse, Soriano, Alex, Codina, Carles, Pumarola, Tomás, Carné, Xavier, Gatell, Josep M

Get full text

Cost analysis of adult parenteral nutrition systems: three-compartment bag versus customized by Berlana, David, Sabin, Pilar, Gimeno-Ballester, Vicente, Romero-Jiménez, Rosa, Zapata-Rojas, Amalia, Marquez, Esther, Martínez-Cutillas, Julio, Schoenenberger-Arnaiz, Joan Anton

“…BACKGROUNDParenteral nutrition (PN) is a costly technology used widely to provide nutrition to patients who have an inaccessible or non-functioning intestine…”
Get full text

A Simplification Trial Swritching From Nucleoside Reverse Transcriptase Inhibitors to Once-Daily Fixed-Dose Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV-1-Infected Patients With Virological Suppression by MARTINEZ, Esteban, ARRANZ, José A, BLANCO, José L, MALLOLAS, Josep, LLIBRE, Josep M, CLOTET, Bonaventura, DALMAU, David, SEGURA, Ferran, ARRIBAS, José R, COSIN, Jaime, BARRUFET, Pilar, CASAS, Esperanza, PODZAMCZER, Daniel, FERRER, Elena, CURRAN, Adria, GONZALEZ, Alicia, PICH, Judit, CRUCETA, Ana, ARNAIZ, Joan A, MIRO, José M, GATELL, José M, LONCA, Montserrat, SANZ, José, BARRAGAN, Patricia, RIBERA, Esteban, KNOBEL, Hernando, ROCA, Victor, GUTIERREZ, Félix

Get full text

Dose-Finding Study of Once-Daily Indinavir/Ritonavir Plus Zidovudine and Lamivudine in HIV-Infected Patients by Mallolas, Josep, Blanco, José L, Sarasa, María, Giner, Vicenç, Martinez, Esteban, Garcia-Viejo, Miguel A, Arnaiz, Joan A, Cruceta, Anna, Soy, Dolors, Tuset, Montse, Soriano, Alex, Codina, Carles, Pumarola, Tomás, Carné, Xavier, Gatell, Josep M

“…BACKGROUND:Strategies for treatment of HIV need to be considered in terms of combining potency, safety, and convenience of dosage. However, regimens including…”
Get full text